Novartis' Lutathera Shows Significant Survival Benefit as First-Line Treatment for GEP-NETs

Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with somatostatin receptor-positive well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors.

Leave a Reply

Your email address will not be published. Required fields are marked *